TriSalus Life Sciences (TLSI)

• Market cap: $123M
• 1 day: 12.50%
• 5 days: -2.64%
• 1 month: -0.49%
• 3 months: -9.60%
• 6 months: -28.70%
• Year to date: -50.91%
• 1 year: -50.55%
• 5 years: -66.25%
• 10 years: -66.25%
• Sector: Healthcare
• Industry: Surgical & Medical Instruments & Apparatus

About: TriSalus Life Sciences Inc is engaged in the research, development, and sales of innovative drug delivery technology and immune-oncology therapeutics to improve outcomes in difficult-to-treat liver and pancreatic cancer. It is developing and marketing two product lines Pressure Enabled Drug Delivery (PEDD) infusion systems, in use today, and an investigational agent, nelitolimod (SD-101), which shows potential to enhance immune system response in the treatment of hepatocellular cancer, pancreatic cancer and other liver solid tumors. TriNav is the newest therapy delivery device with SmartValve technology for the proprietary PEDD approach.

Fund manager confidence

Based on 2024 Q3 regulatory filings by fund managers ($100M+ AUM)

57% more first-time investments, than exits

New positions opened: 11 | Existing positions closed: 7

14% more funds holding

Funds holding: 28 [Q2] → 32 (+4) [Q3]

8% more capital invested

Capital invested by funds: $9.22M [Q2] → $9.92M (+$704K) [Q3]

0.83% more ownership

Funds ownership: 6.58% [Q2] → 7.41% (+0.83%) [Q3]

67% less repeat investments, than reductions

Existing positions increased: 3 | Existing positions reduced: 9

Research analyst outlook

4 Wall Street Analysts provided 1 year price targets over the past 3 months

• Low target: $10 147% upside
• Avg. target: $11.13 175% upside
• High target: $12.50 209% upside

4 analyst ratings

• positive: 4 100%
• neutral: 0 0%
• negative: 0 0%

Cantor Fitzgerald Prakhar Agrawal 17% 1-year accuracy 4 / 24 met price target	147% upside $10	Overweight Initiated	17 Dec 2024
Canaccord Genuity William Plovanic 57% 1-year accuracy 26 / 46 met price target	172% upside $11	Buy Maintained	15 Nov 2024
Roth MKM Jason Wittes 55% 1-year accuracy 11 / 20 met price target	172% upside $11	Buy Initiated	11 Nov 2024
Northland Capital Markets Carl Byrnes 60% 1-year accuracy 3 / 5 met price target	209% upside $12.50	Outperform Initiated	25 Oct 2024